Home / Resource Library / A phase 2 study of the PI3K inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)

A phase 2 study of the PI3K inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)

Results of a phase II study investigating parsaclisib for treatment of relapsed marginal zone lymphoma.